Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VX-840 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part A: VX-840 | EXPERIMENTAL | Participants will be randomized to receive single dose of one of different dose levels of VX-840. |
| Part A: Placebo | PLACEBO_COMPARATOR | Participants will receive placebo matched to VX-840. |
| Part B: VX-840 | EXPERIMENTAL | Participants will be randomized to receive multiple doses of one of different dose levels of VX-840. The dose levels will be determined based on the data from Part A. |
| Part B: Placebo | PLACEBO_COMPARATOR | Participants will receive placebo matched to VX-840. |
| Name | Type | Description |
|---|---|---|
| VX-840 | DRUG | Solution for oral administration. |
| Placebo | DRUG | Placebo matched to VX-840 for oral administration. |
Key Inclusion Criteria: * Female participants must be of non-childbearing potential * Body mass index (BMI) of 18.0 to 32.0 kilograms per meter square (kg/m\^2) * A total body weight greater than (\>) 50 kg Key Exclusion Criteria: * History of febrile illness or other acute illness within 14 days...
VX-840 is an investigational small molecule being developed for APOL1-mediated Kidney Disease, a condition affecting kidney function. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
VX-840 is being developed by Vertex Pharmaceuticals Incorporated, a biopharmaceutical company traded on the NASDAQ under the ticker symbol VRTX.
VX-840 is in Phase 1 clinical development. It is an investigational drug and has not been approved for any use. A Phase 1 dose escalation study has been completed.
VX-840 has one completed Phase 1 trial, NCT05324410, which evaluated safety and pharmacokinetics in healthy participants. The trial enrolled 88 participants in the United States and was placebo-controlled and double-blind.
No alternative names for VX-840 have been disclosed. It is identified solely by its investigational code name VX-840.